Annual FCF
-$384.11 M
-$70.93 M-22.65%
31 December 2023
Summary:
Iovance Biotherapeutics annual free cash flow is currently -$384.11 million, with the most recent change of -$70.93 million (-22.65%) on 31 December 2023. During the last 3 years, it has fallen by -$132.19 million (-52.47%). IOVA annual FCF is now -2667330.56% below its all-time high of -$14.40 thousand, reached on 31 December 2009.IOVA Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$61.26 M
+$37.61 M+38.04%
30 September 2024
Summary:
Iovance Biotherapeutics quarterly free cash flow is currently -$61.26 million, with the most recent change of +$37.61 million (+38.04%) on 30 September 2024. Over the past year, it has increased by +$26.40 million (+30.12%).IOVA Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$374.08 M
+$26.40 M+6.59%
30 September 2024
Summary:
Iovance Biotherapeutics TTM free cash flow is currently -$374.08 million, with the most recent change of +$26.40 million (+6.59%) on 30 September 2024. Over the past year, it has increased by +$3.22 million (+0.85%). IOVA TTM FCF is now -2597684.72% below its all-time high of -$14.40 thousand, reached on 31 December 2009.IOVA TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IOVA Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -22.6% | +30.1% | +0.8% |
| 3 y3 years | -52.5% | +9.1% | -28.9% |
| 5 y5 years | -274.9% | -41.1% | -166.4% |
IOVA Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -52.5% | at low | at high | +51.5% | -40.9% | +7.7% |
| 5 y | 5 years | -274.9% | at low | -47.2% | +51.5% | -166.4% | +7.7% |
| alltime | all time | <-9999.0% | at low | <-9999.0% | +51.5% | <-9999.0% | +7.7% |
Iovance Biotherapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$61.26 M(-38.0%) | -$374.08 M(-6.6%) |
| June 2024 | - | -$98.87 M(-21.8%) | -$400.48 M(-1.1%) |
| Mar 2024 | - | -$126.45 M(+44.5%) | -$405.08 M(+5.5%) |
| Dec 2023 | -$384.11 M(+22.6%) | -$87.50 M(-0.2%) | -$384.11 M(+1.8%) |
| Sept 2023 | - | -$87.66 M(-15.3%) | -$377.30 M(+6.4%) |
| June 2023 | - | -$103.47 M(-1.9%) | -$354.68 M(+6.4%) |
| Mar 2023 | - | -$105.48 M(+30.7%) | -$333.42 M(+6.5%) |
| Dec 2022 | -$313.18 M(+18.0%) | -$80.69 M(+24.1%) | -$313.18 M(+6.6%) |
| Sept 2022 | - | -$65.04 M(-20.9%) | -$293.91 M(-0.8%) |
| June 2022 | - | -$82.21 M(-3.6%) | -$296.25 M(+6.7%) |
| Mar 2022 | - | -$85.24 M(+38.8%) | -$277.66 M(+4.6%) |
| Dec 2021 | -$265.51 M(+5.4%) | -$61.42 M(-8.8%) | -$265.51 M(-8.5%) |
| Sept 2021 | - | -$67.38 M(+5.9%) | -$290.13 M(+3.2%) |
| June 2021 | - | -$63.62 M(-13.0%) | -$281.11 M(+8.5%) |
| Mar 2021 | - | -$73.10 M(-15.0%) | -$259.09 M(+2.8%) |
| Dec 2020 | -$251.93 M(+51.9%) | -$86.03 M(+47.4%) | -$251.93 M(+12.9%) |
| Sept 2020 | - | -$58.36 M(+40.3%) | -$223.15 M(+7.2%) |
| June 2020 | - | -$41.61 M(-36.9%) | -$208.20 M(+3.2%) |
| Mar 2020 | - | -$65.93 M(+15.2%) | -$201.82 M(+21.7%) |
| Dec 2019 | -$165.81 M(+61.8%) | -$57.25 M(+31.9%) | -$165.81 M(+18.1%) |
| Sept 2019 | - | -$43.42 M(+23.2%) | -$140.40 M(+12.0%) |
| June 2019 | - | -$35.23 M(+17.8%) | -$125.38 M(+9.5%) |
| Mar 2019 | - | -$29.91 M(-6.1%) | -$114.49 M(+11.8%) |
| Dec 2018 | -$102.45 M(+28.5%) | -$31.84 M(+12.2%) | -$102.45 M(+12.0%) |
| Sept 2018 | - | -$28.39 M(+16.6%) | -$91.51 M(+7.9%) |
| June 2018 | - | -$24.34 M(+36.2%) | -$84.83 M(+8.7%) |
| Mar 2018 | - | -$17.87 M(-14.5%) | -$78.01 M(-2.2%) |
| Dec 2017 | -$79.74 M(+133.2%) | -$20.91 M(-3.7%) | -$79.74 M(+11.2%) |
| Sept 2017 | - | -$21.71 M(+23.9%) | -$71.73 M(+13.9%) |
| June 2017 | - | -$17.52 M(-10.6%) | -$62.95 M(+27.9%) |
| Mar 2017 | - | -$19.60 M(+52.0%) | -$49.24 M(+44.0%) |
| Dec 2016 | -$34.19 M | -$12.90 M(-0.3%) | -$34.19 M(+22.0%) |
| Sept 2016 | - | -$12.93 M(+240.2%) | -$28.02 M(+47.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2016 | - | -$3.80 M(-16.5%) | -$19.00 M(-4.2%) |
| Mar 2016 | - | -$4.55 M(-32.3%) | -$19.84 M(+1.6%) |
| Dec 2015 | -$19.52 M(+90.9%) | -$6.73 M(+71.9%) | -$19.52 M(+11.4%) |
| Sept 2015 | - | -$3.92 M(-15.6%) | -$17.53 M(+13.1%) |
| June 2015 | - | -$4.64 M(+9.3%) | -$15.51 M(+27.2%) |
| Mar 2015 | - | -$4.24 M(-10.5%) | -$12.20 M(+19.3%) |
| Dec 2014 | -$10.22 M(+178.3%) | -$4.74 M(+150.8%) | -$10.22 M(+32.2%) |
| Sept 2014 | - | -$1.89 M(+42.7%) | -$7.74 M(+23.1%) |
| June 2014 | - | -$1.32 M(-41.7%) | -$6.29 M(+11.4%) |
| Mar 2014 | - | -$2.27 M(+0.8%) | -$5.64 M(+53.6%) |
| Dec 2013 | -$3.67 M(+63.9%) | -$2.25 M(+412.1%) | -$3.67 M(+158.4%) |
| Sept 2013 | - | -$439.80 K(-35.5%) | -$1.42 M(+12.6%) |
| June 2013 | - | -$681.90 K(+127.3%) | -$1.26 M(-29.1%) |
| Mar 2013 | - | -$300.00 K(<-9900.0%) | -$1.78 M(-20.5%) |
| Dec 2012 | -$2.24 M(-64.0%) | $0.00(-100.0%) | -$2.24 M(-54.8%) |
| Sept 2012 | - | -$280.70 K(-76.6%) | -$4.96 M(-21.7%) |
| June 2012 | - | -$1.20 M(+57.9%) | -$6.33 M(-1.3%) |
| Mar 2012 | - | -$760.20 K(-72.1%) | -$6.42 M(+3.1%) |
| Dec 2011 | -$6.22 M(+902.0%) | -$2.72 M(+64.6%) | -$6.22 M(+60.9%) |
| Sept 2011 | - | -$1.65 M(+28.9%) | -$3.87 M(+66.2%) |
| June 2011 | - | -$1.28 M(+127.2%) | -$2.33 M(+106.1%) |
| Mar 2011 | - | -$564.50 K(+54.0%) | -$1.13 M(+81.8%) |
| Dec 2010 | -$620.80 K(+4211.1%) | -$366.60 K(+223.6%) | -$620.80 K(+138.3%) |
| Sept 2010 | - | -$113.30 K(+34.2%) | -$260.50 K(+74.0%) |
| June 2010 | - | -$84.40 K(+49.4%) | -$149.70 K(+121.1%) |
| Mar 2010 | - | -$56.50 K(+796.8%) | -$67.70 K(+370.1%) |
| Dec 2009 | -$14.40 K(-75.9%) | -$6300.00(+152.0%) | -$14.40 K(-41.0%) |
| Sept 2009 | - | -$2500.00(+4.2%) | -$24.40 K(+6.6%) |
| June 2009 | - | -$2400.00(-25.0%) | -$22.90 K(-34.6%) |
| Mar 2009 | - | -$3200.00(-80.4%) | -$35.00 K(-41.5%) |
| Dec 2008 | -$59.80 K | -$16.30 K(+1530.0%) | -$59.80 K(+37.5%) |
| Sept 2008 | - | -$1000.00(-93.1%) | -$43.50 K(+2.4%) |
| June 2008 | - | -$14.50 K(-48.2%) | -$42.50 K(+51.8%) |
| Mar 2008 | - | -$28.00 K | -$28.00 K |
FAQ
- What is Iovance Biotherapeutics annual free cash flow?
- What is the all time high annual FCF for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics annual FCF year-on-year change?
- What is Iovance Biotherapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics quarterly FCF year-on-year change?
- What is Iovance Biotherapeutics TTM free cash flow?
- What is the all time high TTM FCF for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics TTM FCF year-on-year change?
What is Iovance Biotherapeutics annual free cash flow?
The current annual FCF of IOVA is -$384.11 M
What is the all time high annual FCF for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high annual free cash flow is -$14.40 K
What is Iovance Biotherapeutics annual FCF year-on-year change?
Over the past year, IOVA annual free cash flow has changed by -$70.93 M (-22.65%)
What is Iovance Biotherapeutics quarterly free cash flow?
The current quarterly FCF of IOVA is -$61.26 M
What is the all time high quarterly FCF for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high quarterly free cash flow is $0.00
What is Iovance Biotherapeutics quarterly FCF year-on-year change?
Over the past year, IOVA quarterly free cash flow has changed by +$26.40 M (+30.12%)
What is Iovance Biotherapeutics TTM free cash flow?
The current TTM FCF of IOVA is -$374.08 M
What is the all time high TTM FCF for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high TTM free cash flow is -$14.40 K
What is Iovance Biotherapeutics TTM FCF year-on-year change?
Over the past year, IOVA TTM free cash flow has changed by +$3.22 M (+0.85%)